Bank of Montreal Can trimmed its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 18.1% in the first quarter, HoldingsChannel reports. The firm owned 9,708 shares of the medical research company’s stock after selling 2,150 shares during the quarter. Bank of Montreal Can’s holdings in Bio-Rad Laboratories were worth $2,967,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. First Citizens Bank & Trust Co. increased its stake in Bio-Rad Laboratories by 38.0% during the 1st quarter. First Citizens Bank & Trust Co. now owns 1,720 shares of the medical research company’s stock worth $526,000 after purchasing an additional 474 shares in the last quarter. Segall Bryant & Hamill LLC increased its stake in Bio-Rad Laboratories by 2.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 25,212 shares of the medical research company’s stock worth $5,855,000 after purchasing an additional 573 shares in the last quarter. Vanguard Group Inc increased its stake in Bio-Rad Laboratories by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 1,832,968 shares of the medical research company’s stock worth $573,701,000 after purchasing an additional 35,261 shares in the last quarter. Avalon Advisors LLC bought a new stake in Bio-Rad Laboratories during the 1st quarter worth approximately $3,395,000. Finally, Westfield Capital Management Co. LP increased its stake in Bio-Rad Laboratories by 8.4% during the 4th quarter. Westfield Capital Management Co. LP now owns 376,018 shares of the medical research company’s stock worth $87,319,000 after purchasing an additional 29,265 shares in the last quarter. 64.30% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on BIO shares. Barclays increased their target price on Bio-Rad Laboratories from $340.00 to $350.00 and gave the stock an “overweight” rating in a research note on Thursday, May 9th. Deutsche Bank increased their target price on Bio-Rad Laboratories from $330.00 to $350.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. ValuEngine raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research raised Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Friday, February 22nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Bio-Rad Laboratories has an average rating of “Buy” and a consensus price target of $365.00.
Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, May 8th. The medical research company reported $1.65 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.53. The company had revenue of $553.98 million during the quarter, compared to analysts’ expectations of $548.82 million. Bio-Rad Laboratories had a net margin of 24.84% and a return on equity of 4.15%. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 7.15 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Bank of Montreal Can Lowers Position in Bio-Rad Laboratories, Inc. (BIO)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2019/05/16/bank-of-montreal-can-lowers-position-in-bio-rad-laboratories-inc-bio.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Story: Why Invest in Dividend Achievers?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.